A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
Trial details
- Registry ID
- NCT06990984
- Drugs studied
- D-Mannitol, TTI-0102: cysteamine-pantetheine disulfide
TrialRedline tracks 2 clinical trials sponsored by Thiogenesis Therapeutics, Inc.: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)NCT06990984 | D-Mannitol, TTI-0102: cysteamine-pantetheine disulfide | Not yet recruiting | 2027-06Estimated |
| A Study to Assess TTI-0102 vs Placebo in MELAS PatientsNCT06644534 | TTI-0102 | Completed | 2026-01-12Actual |
Names as written in the registry records.
NCT06644534 · Thiogenesis Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 12 participants (planned). After: 9 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Apr 2026. After: 12 Jan 2026.
Before: Recruiting. After: Completed.
NCT06990984 · Thiogenesis Therapeutics, Inc.
Before: Sep 2026. After: Jun 2027.